|
1
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng T, Cui D and Gao L: Glioma: An
overview of current classifications, characteristics, molecular
biology and target therapies. Front Biosci. 20:1104–1115. 2015.
View Article : Google Scholar
|
|
3
|
Ostrom QT, Gittleman H, Stetson L, Virk S
and Barnholtz-Sloan JS: Epidemiology of intracranial gliomas. Prog
Neurol Surg. 30:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qaddoumi I, Sultan I and Gajjar A: Outcome
and prognostic features in pediatric gliomas: A review of 6212
cases from the Surveillance, Epidemiology, and End Results
database. Cancer. 115:5761–5770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu Q, Xu L, Wang C, Fan W, Yan H and Li Q:
MicroRNA-124-3p represses cell growth and cell motility by
targeting EphA2 in glioma. Biochem Biophys Res Commun.
503:2436–2442. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang BQ, Yang B, Yang HC, Wang JY, Hu S,
Gao YS and Bu XY: MicroRNA-499a decelerates glioma cell
proliferation while accelerating apoptosis through the suppression
of Notch1 and the MAPK signaling pathway. Brain Res Bull.
142:96–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu J, He J, Huang H, Peng R and Xi J:
MicroRNA-423-3p promotes glioma growth by targeting PANX2. Oncol
Lett. 16:179–188. 2018.PubMed/NCBI
|
|
9
|
Ramachandran SS, Muiwo P, Ahmad HM, Pandey
RM, Singh S, Bakhshi S, Kumar L, Bhattacharya A and Gupta YK:
miR-505-5p and miR-193b-3p: Potential biomarkers of imatinib
response in patients with chronic myeloid leukemia. Leuk Lymphoma.
58:1981–1984. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Q, Jia C, Wang P, Xiong M, Cui J, Li
L, Wang W, Wu Q, Chen Y and Zhang T: MicroRNA-505 identified from
patients with essential hypertension impairs endothelial cell
migration and tube formation. Int J Cardiol. 177:925–934. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qin Z, He W, Tang J, Ye Q, Dang W, Lu Y,
Wang J, Li G, Yan Q and Ma J: MicroRNAs orovide feedback regulation
of epithelial-mesenchymal transition induced by growth factors. J
Cell Physiol. 231:120–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding J, Cui X and Liu Q: Emerging role of
HMGB1 in lung diseases: Friend or foe. J Cell Mol Med.
21:1046–1057. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng
YJ, Lin FY, Chen YL, Hung CY, Chen WC, Chen YH, et al:
High-mobility group box 1-mediated matrix metalloproteinase-9
expression in non-small cell lung cancer contributes to tumor cell
invasiveness. Am J Respir Cell Mol Biol. 43:530–538. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song B, Song WG, Li ZJ, Xu ZF, Wang XW,
Wang CX and Liu J: Effect of HMGB1 silencing on cell proliferation,
invasion and apoptosis of MGC-803 gastric cancer cells. Cell
Biochem Funct. 30:11–17. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yao X, Zhao G, Yang H, Hong X, Bie L and
Liu G: Overexpression of high-mobility group box 1 correlates with
tumor progression and poor prognosis in human colorectal carcinoma.
J Cancer Res Clin Oncol. 136:677–684. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan C, Wang Y, Qiu MK, Wang SQ, Liu YB,
Quan ZW and Ou JM: Knockdown of HMGB1 inhibits cell proliferation
and induces apoptosis in hemangioma via downregulation of AKT
pathway. J Biol Regul Homeost Agents. 31:41–49. 2017.PubMed/NCBI
|
|
17
|
Zhang J, Zhang J, Qiu W, Zhang J, Li Y,
Kong E, Lu A, Xu J and Lu X: MicroRNA-1231 exerts a tumor
suppressor role through regulating the EGFR/PI3K/AKT axis in
glioma. J Neurooncol. 139:547–562. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma C, Wei F, Xia H, Liu H, Dong X, Zhang
Y, Luo Q, Liu Y and Li Y: MicroRNA-10b mediates TGF-β1-regulated
glioblastoma proliferation, migration and epithelial-mesenchymal
transition. Int J Oncol. 50:1739–1748. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang Y, Wang X, Zhang J and Lai R:
MicroRNA-599 suppresses glioma progression by targeting RAB27B.
Oncol Lett. 16:1243–1252. 2018.PubMed/NCBI
|
|
21
|
Zhang C, Yang X, Fu C and Liu X:
Combination with TMZ and miR-505 inhibits the development of
glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling
pathway. Gene. 672:172–179. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma C, Xu B, Husaiyin S, Wang L,
Wusainahong K, Ma J, Zhu K and Niyazi M: MicroRNA-505 predicts
prognosis and acts as tumor inhibitor in cervical carcinoma with
inverse association with FZD4. Biomed Pharmacother. 92:586–594.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu YJ, Li W, Chang F, Liu JN, Lin JX and
Chen DX: MicroRNA-505 is downregulated in human osteosarcoma and
regulates cell proliferation, migration and invasion. Oncol Rep.
39:491–500. 2018.PubMed/NCBI
|
|
24
|
Lu L, Qiu C, Li D, Bai G, Liang J and Yang
Q: MicroRNA-505 suppresses proliferation and invasion in hepatoma
cells by directly targeting high-mobility group box 1. Life Sci.
157:12–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stoetzer OJ, Fersching DM, Salat C,
Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V,
Siegele B, et al: Circulating immunogenic cell death biomarkers
HMGB1 and RAGE in breast cancer patients during neoadjuvant
chemotherapy. Tumour Biol. 34:81–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meng Q, Zhao J, Liu H, Zhou G, Zhang W, Xu
X and Zheng M: HMGB1 promotes cellular proliferation and invasion,
suppresses cellular apoptosis in osteosarcoma. Tumour Biol.
35:12265–12274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang J, Liu C and Hou R: Knockdown of
HMGB1 improves apoptosis and suppresses proliferation and invasion
of glioma cells. Chin J Cancer Res. 26:658–668. 2014.PubMed/NCBI
|
|
28
|
Wang XJ, Zhou SL, Fu XD, Zhang YY, Liang
B, Shou JX, Wang JY and Ma J: Clinical and prognostic significance
of high-mobility group box-1 in human gliomas. Exp Ther Med.
9:513–518. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu L, Zhang D, Xu Y, Bai G, Lv Y and Liang
J: miR-505 enhances doxorubicin-induced cytotoxicity in
hepatocellular carcinoma through repressing the Akt pathway by
directly targeting HMGB1. Biomed Pharmacother. 104:613–621. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar
|
|
31
|
Rathod SS, Rani SB, Khan M, Muzumdar D and
Shiras A: Tumor suppressive miRNA-34a suppresses cell proliferation
and tumor growth of glioma stem cells by targeting Akt and Wnt
signaling pathways. FEBS Open Bio. 4:485–495. 2014. View Article : Google Scholar : PubMed/NCBI
|
